B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified
Conditions
Keywords
CAR T-cell, CAR19T2 T cell, refractory/relapsed B-cell acute lymphoblastic leukemia, refractory/relapsed Lymphoma
Brief summary
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Detailed description
CD19 CAR-T cells treating B-cell hematological malignancies have achieved unprecedented success. In this study, we investigated new third-generation autologous T cells (CAR19T2 T cells) genetically modified with humanized anti-CD19 construct incorporating CD28 and Toll-like receptor 2 (TLR2) costimulatory domains. CAR19T2 T cells will be modified before the infusion to those which could identify and kill the tumor cells (CD19+ cells). This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor T cell (CAR19T2 T Cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Interventions
BIOLOGICALCD19 CAR T-Cell(CAT19T2)
Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
Sponsors
Guangdong Zhaotai Cell Bio-tech Co., LTD
Zhujiang Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. ≥1 year old and ≤18 years. 2. Patients with relapsed and/or refractory CD19-positive B-cell acute leukemia/lymphoma. 3. Leukemia/lymphoma relapsed after allogeneic hematopoietic stem cell transplantation within four weeks, all immunosuppressive agents were stopped for at least four weeks, and no active graft-versus-host disease(GVHD) was detonated. 4. Lansky play (≤16 years old) scale ≥60% or Karnofsky (\>16 years old) score ≥60% and Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory to assess the performance score. 5. Adequate vascular access leukapheresis procedure. Absolute Lymphocyte count (ALC) greater than or equal to 100 cells/μL. 6. Adequate renal, hepatic, pulmonary, and cardiac function is defined as the following: * Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 5 upper limit of normal (ULN), Total bilirubin ≤2 x ULN. * A serum creatinine based on age/gender as follows: 1 to \< 2 years: maximum serum creatinine 0.6 mg/dL (both male and female);2 to \< 6 years: maximum serum creatinine 0.8 mg/dL (both male and female); 6 to \< 10 years: maximum serum creatinine 1 mg/dL (both male and female); 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL (both male and female); 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female); \>=16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female). * Baseline oxygen saturation \> 92% on room air. * Echocardiogram or left ventricular ejection fraction (LVEF) greater than or equal to 45% confirmed by echocardiogram, no evidence of pericardial effusion (except trace or physiological), and no clinically significant arrhythmias. 7. Life expectancy of greater than or equal to 3 months. 8. Patients or legal guardians must sign an informed consent.
Exclusion criteria
1. Prior received any other CAR T cell and tumor vaccine treatment. 2. Patient with a previous history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. 3. Patient with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment. 4. Acute GVHD grade II-IV (Glucksberg criteria) or chronic GVHD requiring systemic treatment within 4 weeks before enrollment. 5. History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, etc. (Except for CNS involvement of underlying hematological malignancy) 6. Severe psychological disorder or psychiatric illness. 7. Combined with life-threatening severe organ failure. 8. Major non-medicinal surgery within four weeks. 9. Received other clinical trials within four weeks. 10. Women who are pregnant or breastfeeding. 11\. The following drugs patients must be stopped prior to leukapheresis: * Tyrosine Kinase Inhibitor (TKI) must be discontinued more than or equal to 3 days before collection. * Salvage chemotherapy must be stopped \> 2 weeks and intrathecal chemotherapy in the 7 days prior to collection. * Systemic steroid therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone in the 7 days before collection. * Donor lymphocyte infusions (DLI) and Immunosuppressive therapies within 4 weeks before collection. * Received clofarabine or cladribine within 3 months prior to collection. * Receive blinatumomab within 4 weeks, inotuzumab ozogamicin, and rituximab within 4 months, and alemtuzumab within 6 months before collection. 12\. Tyrosine Kinase Inhibitor within 1 week and asparaginase within 4 weeks prior to CAR T-cell infusion. 13\. In the opinion of the PI, patients are present for any condition, not for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | 3 months | A total number of patients achieved a Complete response (CR) or CR with incomplete blood count recovery (CRi) on Day 28 and three months by an independent review committee(IRC) assessment, as evaluated by peripheral blood, bone marrow, central nervous system (CNS) symptoms, physical exam (PE), and cerebrospinal fluid(CSF). |
| The maximum tolerated dose(MTD) of CAR19T2 T cells | 24 weeks | The maximum tolerated dose(MTD) of CD19-positive relapsed/ refractory acute leukemia/lymphoma treated with CAR19T2 T cells. |
| Adverse Events (AEs) | 3 years | Type, frequency and severity of adverse events (AEs), serious adverse events (SAE), and laboratory abnormalities (overall and in clinical, histological and molecular subgroups). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CAR-T cell expansion level | 24 months | Copies numbers of CAR in peripheral blood (PB) and/or bone marrow (BM), CSF and lymph nodes, etc. |
| The duration of CAR T cell persistence | 24 months | The duration of CAR T cell persistence in peripheral blood(PB) and/or bone marrow(BM), CSF and lymph nodes, etc. |
| Rate of hematopoietic stem cell transplant (HSCT) after CAR19T2 T cell infusion | Up to 3 years after CAR19T2 T infusion | Percentage of subjects who achieve a response after CAR19T2 T cell infusion and then proceed to HSCT. |
| Minimal residual disease (MRD) negative response rate | Up to 12 months after infusion | Patients achieving CR or CRi and a negative MRD bone marrow. |
| Time to peak concentration of CAR19T2 T cell and cytokines. | 12 months | Pharmacokinetics of CAR19T2 T cell in Time to peak concentration. |
| Area under the curve of CAR19T2 T cell and cytokines. | 12 months | Pharmacokinetics of CAR19T2 T cell in Area under the curve. |
| Incidence of hypogammaglobulinaemia | 12 months | Incidence and duration of hypogammaglobulinaemia. |
| Maximum concentration of CAR19T2 T cell and cytokines. | 12 months | Pharmacokinetics of CAR19T2 T cell in Maximum concentration. |
| Event-free survival (EFS) | Up to 3 years after infusion | Time from CAR19T2 T cell infusion to progressive disease (PD), disease relapse, start of a new anticancer therapy, or death from any cause, whichever occurs first. |
| Overall survival (OS) | Up to 3 years after infusion | Time from CAR19T2 T cell infusion to time of death due to any cause. |
Countries
China
Outcome results
None listed